Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder	Recruiting	Phase 3	2024-01-26		NCT05918094

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Sun Yat-sen University	606

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Harbin Medical University Cancer Hospital	Harbin	China	51
Henan Cancer Hospital	Zhengzhou	China	98
Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	China	13
Sun Yat-sen University Cancer Center	Guangzhou	China	315
The Affliated Cancer Hospital of Guizhou Medical University	Guiyang	China	1
The First Affiliated Hospital of Nanchang University	Nanchang	China	77
The Second Affiliated Hospital of Kunming Medical University	Kunming	China	16
The Second Hospital of Dalian Medical University	Dalian	China	15
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology	Wuhan	China	7
West China Hospital of Sichuan University	Chengdu	China	68